cyrilzakka/clinical-trials huggingface dataset:
CTHRC1: A Biomarker for Evaluation of Rheumatoid Arthritis Disease Activity

The purpose of the study is to determine whether plasma levels of the collagen triple helix repeat containing (CTHRC1) protein can serve as a blood-based biomarker for diagnosis of rheumatoid arthritis (RA) ,and furthermore its correlation with disease activity

Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disease of synovial joints. Characterized by periods of flares with high disease activity involving both a systemic immune response and tissue-specific inflammatory events that can lead to erosive joint and bone destruction and subsequent disability . Currently, diagnosis of RA is based mainly on the extent of tenderness and swelling of the joints , levels of acute-phase reactants such as C-reactive protein (CRP) ,erythrocyte sedimentation rate(ESR) , high titers of rheumatoid factor (RF) and high titers of antibodies against cyclic citrullinated peptide (anti-CCP) in the plasma .Recently, reported increased levels of collagen triple helix repeat containing 1 protein (CTHRC1) are strongly associated with the severity of murine proteoglycan-induced arthritis and collagen antibody-induced murine arthritis (CAIA) , further CTHRC1 expression in murine experimental arthritis is increased in the synovium and specifically detected in activated murine , located at the synovial intimal lining and at the bone-pannus interface .Of interest,The expression pattern of CTHRC1 in pannus, its role in the function of FLS relevant to cartilage damage in RA, and CTHRC1's association with disease severity in murine arthritis raised the question of whether CTHRC1 could be used as a marker for RA diagnosis and monitoring of disease activity in patients .

Eligibility Criteria:
Inclusion Criteria:

* patients diagnosed as RA
* age more than 18 years

Exclusion Criteria:

* other rheumatological diseases Malignancies Hepatic diseases
Increased Risk of ADHD Among Children With Bilateral Congenital Cataracts

In this study, the investigators conducted a cross-sectional, face-to-face investigation to evaluate the behavioral and psychological disorders and the risk of ADHD among children with bilateral congenital cataracts using the Conners'Parent Rating Scale (CPRS) questionnaire, an assessment tool for screening ADHD that obtains parental reports of childhood behavioral problems in research and clinical settings.15-17 Age-matched children with normal vision and the Chinese urban norm were used as controls.


Eligibility Criteria:
Inclusion Criteria:

* CC children and NV children aged 3-8 years presenting to the Zhognshan Ophthalmic Center between July and December 2016.

Exclusion Criteria:

* Patients complicated with systemic manifestations, such as Lowe syndrome, Marfan syndrome, and Down syndrome, were excluded.
Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating

This study is based on the hypothesis that terazosin, a blocker of alpha-1 receptors, will be effective in reducing excessive sweating caused by antidepressant treatment, and will have minimal adverse effects.

Sweating is a common and bothersome side effect of treatment with antidepressants. Most or all antidepressants have been clearly shown to cause excessive sweating. It is unclear to what extent excessive sweating caused by antidepressants becomes less or goes away with time. In many instances, it continues to be a problem even after 6 or more months on the antidepressant.

There is no generally accepted treatment for excessive sweating. This study has been designed to study whether terazosin is effective in reducing antidepressant-induced sweating, and whether it is well-tolerated and acceptable to patients. In addition, secondary objectives of this study are to determine the time taken for patients to respond to terazosin, the usual doses needed for improvement, and the extent of reduction in sweating. This information will not only help doctors in using terazosin for this purpose in their patients, but will help in designing further studies of this treatment.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of a Depressive disorder (Diagnostic and Statistical Manual of Mental Disorders - IV-TR)
* Presence of excessive sweating by self-report
* The excessive sweating started after initiation of an antidepressant and, if treatment with the antidepressant was interrupted, did not persist for more than 4 weeks during that interruption
* Treatment with the antidepressant is deemed to be clinically necessary due to substantial benefit from this antidepressant, and failure to respond to or tolerate an alternative
* Excessive sweating has persisted for at least 4 weeks prior to baseline assessment
* The excessive sweating is rated by the patient as at least moderately bothersome.
* Episodes of excessive sweating occur at least twice a week for last 4 weeks

Exclusion Criteria:

* Presence of another known disease that could potentially cause excessive sweating
* Failure to respond to antiadrenergic (reducing activity of the sympathetic nervous system) treatment in the past
* Blood pressure less than 110 mm Hg systolic at the screening or baseline visits
* Orthostatic hypotension by history or on assessment at the screening or baseline visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes).
* Current antihypertensive treatment
* History of significant cardiac disease, including coronary artery disease
* Current use of phosphodiesterase type 5 inhibitors: sildenafil (Viagra™), tadalafil (CialisTM), or vardenafil (LevitraTM)
* History of priapism (persistent and painful erection)
Second Window Indocyanine Green for All Nervous System Tumors

The study is being conducted to determine if a same-day, low-dose intravenous (into a vein) injection of indocyanine green (ICG) (FDA-approved dye) being detected by using an imaging system can be a useful tool in identifying and differentiating tumor tissue from normal tissues.


Eligibility Criteria:
Inclusion Criteria:

1. Adult patients 18 years of age and older
2. Patients presenting with a nervous system tumor presumed to be resectable and at risk for local recurrence on pre-operative assessment
3. Good operative candidates, as determined by the treating physician and multidisciplinary team
4. Subjects capable of giving informed consent

Exclusion Criteria:

1. Pregnant women, as determined by urinary or serum beta hCG within 48 hours of surgery
2. Subjects with a history of iodide allergies
3. Vulnerable patient populations
4. Patients unable to participate in the consent process
5. Patients with history of uncontrolled HTN (requiring ER admission or ≥ 3 BP medications)
Testosterone Replacement in Renal Failure

The purpose of this trial is to evaluate the effect of testosterone replacement in men with renal failure (on dialysis) who also have low testosterone. Specifically, the investigators will assess the change in requirement of Erythropoietin Stimulating agents.

Testosterone replacement can increase hemoglobin count. This can therefore decrease the requirement of Erythropoietin Stimulating agents.

Eligibility Criteria:
Inclusion Criteria:

1. Men between ages of 18-80 years of age.
2. Renal failure on hemodialysis
3. Free testosterone \<5 ng/dl.
4. Willing to be randomized to intramuscular (IM) testosterone or placebo
5. Currently getting intravenous Epoetin alfa

Exclusion Criteria:

1. Use of testosterone treatment currently or in the past 6 months, including use of over the counter androgen containing health supplements.
2. Congestive heart Failure, class III or IV.
3. Baseline hemoglobin of \> 12 g/dl.
4. Allergic reactions to testosterone Vehicle (i.e. Peanut oil)
5. prostate specific antigen\>4 ng/ml.
6. History of Prostate Cancer.
7. Liver enzymes \>twice the upper limit of normal.
8. HIV or hepatitis C.
9. Severe untreated obstructive sleep apnea (defined as apnea-hypopnea index\> 30).
10. Subjects on warfarin or other blood thinners.
11. Active infection (such as foot ulcer)
12. History of adverse events with testosterone use in past.
Association Between Post-covid Infection Status and Perioperative Morbidity: A Ambispective Cohort Study

With the knowledge of currently transmitted omicron variant being less virulent, over 90 percent of the Chinese population is fully vaccinated, and the Chinese health workers have sufficient experience treating the illness. China 's epidemic prevention and control has entered a new stage to restore the normal functioning of society and basic medical services, On Dec, 7, China released a circular on further optimizing its COVID-19 response, announcing 10 new prevention and control measures.This has marked the watershed for sharply increased number of elective surgical patients diagnosed with COVID-19 during preoperativley, fully recovered or during recovery.

Beijing faced a wave of omicron infection starting that would result in of a wide range of population infections. At which time there is limited evidence regarding the optimal timing of surgery following SARS-CoV-2 infection especially for omiron among Chinsese patients .This study intends to explore the relationship between the incidence of postoperative complications after elective surgery and COVID-19 infection in Peking Union Medical College Hospital, and provide data support for the policy formulation of elective surgical timing for patients after COVID-19 infection.


Eligibility Criteria:
Inclusion Criteria:

1. All patients having pre-operative SARS-CoV-2 infection diagnosis Dec 1st 2022 to Feb 28th 2023.

\[The COVID-19 diagnosis is based on either (a) a positive RT-PCR nasopharyngeal swab, (b) positive antigen rest before surgery, or (c) clinical diagnosis made before surgery\].

Exclusion Criteria:

1. Patients diagnosed with SARS-CoV-2 infection on the day of surgery or during postoperative days.
2. Day surgery or outpatient surgery.
3. Patients unwilling to participate or provide COVID-19-related information.
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.

Participants diagnosed with severe SCD will receive nula-cel via IV infusion following myeloablative conditioning in an autologous HSCT setting.

Eligibility Criteria:
Inclusion Criteria:

* ≥12 to ≤ 40 years
* Severe disease, as defined by having experienced at least one of the following SCD-related events despite appropriate supportive care measures:
* recurrent severe VOC (≥ 4 episodes in the preceding 2 years)
* ACS (≥ 2 episodes in the prior 2 years with at least one episode in the past year)
* Lansky/Karnofsky performance status of ≥ 80

Exclusion Criteria:

* Available 10/10 HLA-matched sibling donor
* Prior HSCT or gene therapy
* Prior or current malignancy or myeloproliferative or a significant coagulation or immunodeficiency disorder
* Clinically significant and active bacterial, viral, fungal or parasitic infection
* Pregnancy or breastfeeding in a postpartum female
* Presence of a chromosomal abnormality/mutation that may put the participant at an increased risk for MDS or AML per investigator's judgment
Effect on Early Cognition Under Sedation by Rimazole Toluenesulfonate in Old Patient Undergoing Colonoscopy

To investigate the effect on cognition under sedation by Rimazole toluenesulfonatein elderly patients undergoing colonoscopy


Eligibility Criteria:
Inclusion Criteria:

1. ASA I\~II
2. patients will be treatmented by sedation under colonoscopy
3. sign informed consent

Exclusion Criteria:

(1) Preoperative depression and cognitive impairment

（2） Hearing or visual impairment;

（3） Drug abuse, alcoholism or long-term use of antidepressants;

（4） Cardiovascular and cerebrovascular accidents, neurological sequelae, or severe liver and kidney function damage occurred within 6 months

（5） BMI \< 18, BMI \> 30

（6） Confirmed or suspected allergy to the test drug
Dietary Anthocyanins Improve Lipid Metabolism in a Dose - Dependent Manner

In order to study the effect of anthocyanins on the improvement of glucose and lipid metabolism, randomized intervention trials were conducted to compare the effects of anthocyanins on the improvement of glucose and lipid metabolism in different dose groups.To explore the best dose of anthocyanins for the prevention and treatment of anthocyanin metabolic diseases provide an important scientific basis.

In order to study the effect of anthocyanins on the improvement of glucose and lipid metabolism, randomized controlled trials were conducted to enrolled 300 patients with dyslipidemia. The subjects were divided into 0 mg / d, 40 mg / d, 80 mg / d, 320 mg/ d five dose groups, intervention for 12 weeks, comparing different doses of anthocyanins on glucose and lipid metabolism.To explore the best dose of anthocyanins for the prevention and treatment of anthocyanin metabolic diseases provide an important scientific basis.

Eligibility Criteria:
Inclusion Criteria:

* Dyslipidemia
* Subjects with dyslipidemia who also have prediabetes
* The age between 35 and 70 years old

Exclusion Criteria:

* intake of any medicine that affect lipid and glucose metabolism currently or in the preceding 6 months
* dietary supplementation with phytochemicals including anthocyanins in the preceding 2 months
* history of acute or chronic infectious disease, autoimmune disease, cancer, traumatic injury, or surgery in the preceding 1 month
* history of severe chronic disease including AS and CVD, liver or renal dysfunction, and lactation or pregnancy
* Pregnant woman and Breast Feeding Women
Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients

Observational, comparative, cross-sectional study

This study was conducted on G protein-mediated estrogen receptor 1 (GPER-1), which is thought to be effective in preventing the development of diabetic retinopathy (DR). There are studies proving that GPER-1 prevents neuroprotective effects and vascular pathology in many tissues. In the study, serum GPER-1 and oxidative stress biomarker levels were compared in diabetic patients and healthy control groups. GPER-1 was found to be significantly increased in diabetic patients. In addition, a positive correlation was found with oxidant markers. This may lead to new treatment models in the future.

Eligibility Criteria:
Inclusion Criteria:

* 40 individuals were required to have Proliferative Diabetic Retinopathy (PDR);
* 40 were required to have Non-PDR;
* 40 were required to be healthy, without any systemic disease.

Exclusion Criteria:

* Glaucoma,
* Ocular trauma sequelae,
* Pathological myopia,
* Non-diabetic retinopathy,
* A history of previous ocular surgery,
* Endocrine disorders (e.g.,thyroidopathy, adrenal gland disorders, pituitary pathologies),
* Opacities interfering with fundus examination (e.g., corneal opacity, lens opacity, vitreous cloudiness other than diabetic haemorrhage).
Study of Evaluation of Cavir Tab. 0.5mg With Food Effect on Pharmacokinetics and Safety

In this clinical trial, the investigator will clarify the difference in pharmacokinetics between the group single dose Cavir Tab. 0.5mg and single dose Cavir Tab. 0.5mg with high fatty meal for healthy adult volunteer.

The investigators evaluate the effect of food intake on the absorption of Cavir Tab. 0.5mg.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male, aged 19 \~ 45 at screening date
* Subject's weight is in range from -120 percentage to +120 percentage of ideal body weight which is calculated by { height (cm) - 100} \* 0.9.
* The Subject is willing and able to provide written informed consent to participate in the study

Exclusion Criteria:

* Subject has a history of clinically significant disease.
* Subject has a digestive disease (Crohn's disease, ulcer, acute or chronic pancreatitis etc) or abdomen surgery (exclude, simple appendectomy or hernia operation).
* Subject has a hypersensitivity history which is clinically significance or additives.
* Subject is inappropriate to screening (disease history, physical examination, vital sings, electrocardiogram, laboratory test etc.)
* Subject has a laboratory test result as indicated by and one of the following.

  * serum aspartate aminotransferase\> 1.25 \* normal limit
  * serum Total bilirubin \> 1.5 \* normal upper limit
  * serum CPK \> 1.5 \* normal upper limit
  * eGFR(estimated Glomerular Filtration Rate) calaulated by MDRD (Modification of Diet in Renal Disease) formula \< 60 mL/min/1.73m2
* Subject is hypertension(SBP\>140mmHg or DBP\>90mmHg) or hypotension(SBP\<90mmHg, DBP\<60mmHg)
* Subject has a drug abusing history.
* Subject is currently abusing alcohol (more than 210 g/week), caffeine(more than 5cups/day) or smoking(more than half pack).
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3

The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects.


Eligibility Criteria:
Please contact site for information.
Cardiopulmonary Exercise Test in Peripheral Arterial Disease

Aim: To determine whether the lactate threshold during CPET is influenced by the presence of haemodynamically significant PAD.

Assumption: Correction of haemodynamically significant PAD results in an increased LT, measured by CPET.

Design: Prospective study Population: Thirty patients scheduled to undergo surgical or percutaneous treatment of iliofemoral arterial disease for intermittent claudication.

Patients scheduled to undergo surgery or angioplasty of the iliofemoral segment for intermittent claudication will be screened for inclusion. Consenting patients will undergo ABI measurements and CPET before treatment and four weeks after treatment. Study measures will be performed in the respiratory physiology laboratory at University Hospital Aintree. Demographic and medical details will be recorded including gender, age, smoking history and pack years, medical history and treatment and BMI. A record will be made of patuients' latest full blood count which will be routinely available in all participants before the procedure. Ankle-brachial index will be recorded. The subjects will undergo full CPET. This includes recording of baseline spirometry, full ECG monitoring throughout the test, measurement of ventilator parameters and recording of Borg breathlessness and leg fatigue score every minute. At the end of the test the reason for cessation will be documented. The test will be incremental with a 10-20W ramp determined according to baseline MVV aiming for the subject to exercise for 10-12 minutes. The test will involve 3 minutes rest, 2 minutes free-pedal followed by continuous ramping until volition. Recording will continue for 5 minutes recovery

Eligibility Criteria:
Inclusion Criteria:

* Written informed consent, ability to perform a CPET on a cycle ergometer, intermittent claudication as presenting complaint, age ≥18, iliofemoral arterial disease

Exclusion Criteria:

* Critical limb ischaemia, unwillingness to consent, previous amputation or other inability to perform CPET on a cycle ergometer, age \<18, absence of iliofemoral arterial disease, any standard CPET exclusion based on American Thoracic Society/European Respiratory Society Guidelines, including severe arthritis or lower limb abnormality precluding exercise testing, severe hypertension at rest, unstable angina or acute coronary syndrome within the previous 6 weeks, terminal illness/advanced cancer or major psychiatric illness, including dementia, which precludes consent
REALITY MONITORING

Reality-monitoring characterizes the ability to determine whether information was perceived in the environment or only imagined . Impaired reality-monitoring abilities have been associated with hallucinations in patients with schizophrenia and patients with Parkinson's disease.

The investigators hypothesize a link between dopaminergic (DA) transmission and reality-monitoring.

This hypothesis is based on several studies in the literature: 1) DA transmission anomalies are observed in both schizophrenia and Parkinson's disease; 2) DA agonists may induce hallucination; 3) DA antagonists reduce hallucinations and improve reality-monitoring abilities in patients with schizophrenia. In addition, also suggesting a link between mesocorticolimbic connectivity, subcortical DA transmission and reality-monitoring, The investigators have shown that fronto-temporal transcranial Direct Current Stimulation (tDCS) leads:

* on the one hand, to modulate reality-monitoring performance in healthy volunteers and patients;
* on the other hand, to induce subcortical DA release. However, to date, no study has yet explored the direct link between DA transmission and reality-monitoring.

Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers who have given their written informed consent
* Men and women from 18 to 45 years old
* Normal or corrected vision
* Being fluent in French or French for native language
* Being affiliated with health insurance

Exclusion Criteria:

* Healthy volunteers who have given their written informed consent
* Men and women from 18 to 45 years old
* Normal or corrected vision
* Being fluent in French or French for native language
* Being affiliated with health insurance
* Inadmissibility of the subject's consent or refusal
* Working-memory deficit (as controlled with MMSE score\< 23)
* Any past or current psychiatric or somatic condition(as controlled with the Mini International Neuropsychiatric Interview, MINI)
* Any past or current neurological condition
* History of cranio-cerebral trauma, arterial hypotension or hypertension, cardiological or serious medical condition
* Abnormal potassium dosage (below 3.1 mmol/L or above 4.9 mmol/L)
* Anormal ECG
* History of schizophrenia or bipolar disorder in first-degree relatives
* Alcohol-drinking and caffeine intake at least during 24 hours before each session
* Drug therapy excepting contraceptives
* Cardiologic or severe medical conditio
* Pregnancy(checked with a pregnancy autotest), lactation, or insufficient contraceptive measure (precautionary measure)
* Consumption of recreational drugs during the last 6 months
* Known sensitivity to any of the study medication and their excipients
* Lactose intolerance
* Porphyria
* Hepatic insufficiency